Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DD-S052P
- Development stage
- Phase 1
- Lead developer
- HLB
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
DD-S052P is a novel peptide-based therapeutic developed by HLB Science (and its subsidiary Dandi Bioscience) for the treatment of sepsis. It employs a dual mechanism of action: it directly binds to and lyses the membranes of Gram-negative bacteria while simultaneously sequestering the resulting lipopolysaccharide (LPS) or endotoxins from the microenvironment. This approach is designed to not only eliminate the causative bacteria but also to suppress the hyperinflammatory response, or cytokine storm, triggered by endotoxin release—a common complication of traditional antibiotic treatments. DD-S052P is currently being evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy volunteers.
Beyond the preview
Go deeper on DD-S052P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DD-S052P.